FDA Approves Yuflyma as Ninth Adalimumab Biosimilar FDA Approves Yuflyma as Ninth Adalimumab Biosimilar

The manufacturer, Celltrion, is also seeking an interchangeability designation from the FDA, which is tentatively expected in the fourth quarter of 2024.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Rheumatology News Alert Source Type: news